The Board

Advisory Board

The Board

The Academy is Governed by a Board of Directors, the board is comprised of APS members who are elected by the membership and give their time and expertise free of charge.

The Board

Ms Helen Barker
Helen is the managing director of Project-ion Ltd. and program manager in infectious diseases at the University of Oxford. She is an experienced project director in the strategic and technical development of a broad portfolio of R&D; programs. Helen joined the APS in 2001 and the New Scientists Focus Group shortly after. Elected on to the board in 2008, she was appointed APS Chief Scientist in 2012. Graduating from the University of Sunderland in Chemical and Pharmaceutical Science, Helen worked for Bristol-Myers Squibb, primarily developing analytical methods for API and drug product. Subsequently gaining over 15 years of experience working for Pfizer, Helen developed a range of solid, liquid and inhaled programs. Broadening experience across the Pharmaceutical Sciences and R&D;, through successful delivery of projects and initiatives, Helen developed innovative strategies and led global multidisciplinary program teams, both in CMC and pan-R&D.; Therapeutic areas of key experience include infectious and respiratory diseases. Research areas include modernizing medical microbiology with genetics, reactions in the solid state, predictive models and intelligent software. Core interests include development of novel healthcare concepts, business and program development, supporting emerging Pharmaceutical Scientists and engaging key opinion leaders.

Dr Julie Cahill
Julie is Director, Product Development at AstraZeneca R&D.;

Mrs Jo Craig BPharm MRPharmS MAPS
Jo is VP Scientific and Technical Operations at GSK

Dr Geoff Davison
Geoff is CEO of Bionow the membership organisation for life science businesses in the North of England. Prior to this Geoff was founder and Technical Director of Biorite Ltd and Advanced Biomedical Ltd both spin-out companies from the University of Manchester. Geoff has a degree in Biochemistry and a PhD from the School of Pharmacy, University of Manchester where he began his career undertaking postdoctoral research.

Prof Bill Dawson
Bill Dawson retired from Eli Lilly and Co in 1996 after 27 years service and established Bionet Ltd as a health care consultancy working at the interface between academia and industry. At Lilly, Bill was Research Director for 14 years and took 15 compounds into development, two of which reached the market. Latterly, he was Director of Technology Acquisition, Europe, for Lilly. He continues to be a member of the ABPI Academic Liaison Working Group. He is Director of the University of Manchester Medicines Network. He is a non-executive director of Proteome Sciences plc, Antitope Ltd, Pharmovation Ltd and a member of a number of corporate Scientific Advisory Boards. Previously, he was a Director of Biovation Ltd, purchased by Merck KGaA, Enzacta Ltd, merged to form Enact Pharma Ltd and now part of Protherics plc and the Babraham Institute where he served the maximum two terms. He was a Board Member of the Pharmaceutical Licensing Group from 1994-2005. PLG is the professional organisation representing the majority of licensing executives in the UK. He has been active in peer review for MRC, EPSRC and BBSRC and has participated in a number of DTI grant and review panels. He is a Visiting Professor in the School of Science and Mathematics at Sheffield Hallam University and is a Governor of the University of Brighton and of De Montfort University. He is a Fellow of the School and was previously a member of staff in the pharmacology department having completed his PhD at the School under Professor Geoffrey B West Professor Dawson qualified as a pharmacist and specialised in pharmacology. His research interests are in immunopharmacology and in the rational design, selection and progression of new medicines through optimal research and development programmes.

Dr Tommy Dolan
Tommy completed his undergraduate and postgraduate education in Pharmacy at the University of Strathclyde. Following that he undertook post doctoral study at the universities of Strathclyde and Glasgow assessing novel drug carrier systems as immunological adjuvants. He first joined Controlled Therapeutics in 1988 where he was involved in researching the use of hydrogels as novel drug delivery systems for a range of indications. In 1990 Tommy commenced his career at Pfizer Global Research and Development at Sandwich joining as a formulation scientist. Since joining Pfizer he has held a variety of positions in Pharmaceutical Research and Development in that time ultimately heading the department since 2002. Tommy has been involved in the development of a number of drug development programs and wide variety dosage form types in that time many of which are now marketed products. Tommy currently head the departments of Analytical and Pharmaceutical Research and Development at Sandwich and is a past Chair of the Academy of Pharmaceutical Sciences.

Mrs Christine Glover F.R.P.S.
Mrs Christine Glover BSc, FRPharmS, MIPharmM, LFHom Elected Fellow of Royal Pharmaceutical Society of Great Britain - December 1996 Awarded Gold Medal by Academy of Pharmaceutical Science - 2000 Pharmacist - Owner of Glovers Integrated Healthcare in Edinburgh (Previously independent proprietor of Glovers Pharmacy in Edinburgh. (1983 -1998) Current Positions Royal Pharmaceutical Society (Professional & Regulatory body for all 45,000 pharmacists in GB.) Chairman of Trustees for RPS Pension Fund (managing £40 million) Other Director College of Medicine Appointed to MHRA Committee for Safety of Devices May 2005 (reappointed 2009) Appointed as Lay Chairman of MHRA Expert Advisory Group 2007 Member of MHRA Topic Selection Panel for novel technology Member of 2 advisory panels for a global pharmaceutical company Member of Professional Advisory Board for Migraine Action Association Member of advisory board for Academy of Pharmaceutical Sciences Previous experience Royal Pharmaceutical Society of Great Britain Member of Council (1991-2005) President 1998-2001 (Re-elected unopposed for second term) Chairman of RPSGB Benevolent Fund Steering Group (managing £11 million) Chairman and/or member of numerous committees and working parties for RPSGB, including Practice Committee, Corporate Governance Steering Group and Shipman Working party. Member of the Scottish Executive of RPSGB (1988-2005) International Pharmaceutical Federation (FIP) Member of Community Pharmacy Section Executive 1998-2004 Institute of Chartered Accountants Scotland Lay member of Council 2002 – 2007 Member of Executive Group and of Nominating Committee Member of Corporate Governance Steering Group Member of Review Group on Disciplinary Procedures Other Served on Government working parties for CMO, Scottish Executive and BMA. Gave evidence to House of Commons select committee on Drug Abuse Global experience in lecturing, running courses, and public speaking. Achievements Instigated and oversaw complete overhaul of corporate governance for Council of RPSGB. As lay Chairman, chaired Expert Advisory Group, and oversaw successful report, on muta-genicity of metal debris from metal-on-metal hip replacements. Raised profile of pharmacy with Government, media and public during 2 years of presidency. Facilitated linking pharmaceutical science with pharmaceutical practice.

Dr Linda Hakes
Linda Hakes has more than 35 years’ experience in the pharmaceutical industry, having worked for companies such as Glaxo, Marion Merrell Dow, Celltech, Eli Lilly, Schwarz Pharma AG and UCB Biosciences. Her experience covers pharmaceutical development, preclinical development, clinical trial supplies, quality assurance and project leadership. Since 2016 Linda has been an independent consultant with a focus on pharmaceutical development and development strategy. Linda is Chairman of the Academy of Pharmaceutical Sciences, a member of the RPS Assembly and a Vice President of FIP (International Pharmaceutical Federation). She is also a past president of the Industrial Pharmacy Section of FIP, former chairman of the Industrial Pharmacists’ Group and visiting professor at the University of Sunderland. She is eligible to be a Qualified Person and is a Fellow of both the Royal Pharmaceutical Society and FIP.

Prof Mike Hannay DSc
Mike is Managing Director of the East Midlands Academic Health Science Network (AHSN), an NHS organisation charged with transforming the health of 4.6 million people living in the East Midlands and stimulating wealth creation in the region. Mike joined the NHS from Thermo Fisher Scientific where he led the BioPharma Services Division in the United Kingdom as Vice President and General Manager. Prior to joining Thermo Fisher, Mike worked for AstraZeneca where he most recently served as Vice President of Medicines Development leading scientists located in the United Kingdom and the United States. Earlier in his career, Mike led R&D; and operational functions at Teva Pharmaceutical Industries, Sanofi and UCB. Mike has led the development of formulations, devices, drug substance manufacturing processes and associated test methods for a number of innovative new medicines including Brilique, Caprelsa, Neupro, Pentacarinat, ProAir, QVAR EasiBreathe, Seroquel XR and Symbicort pMDI. Mike received his DSc from De Montfort University, his MBA from the Open University, an MSc from the University of Brighton and is a pharmacy graduate of De Montfort University. He is a visiting professor at De Montfort University and Durham University. Mike is a member of the Education Expert Advisory Panel of the Royal Pharmaceutical Society (RPS).

Prof Trevor Jones CBE FMedSci
Professor Jones is a Director of a number of International Pharmaceutical Companies including Allergan Inc (USA) and Sigma Tau (Italy and USA) He was formerly Group R&D; Director and The Wellcome Foundation and Director General of the Association of the British Pharmaceutical Industry (ABPI) He is a visiting professor at King’s College, London and holds honorary degrees and Gold Medals from 6 universities. He has served in various government /international organisation capacities such as a Commissioner for the World Health Organisation (WHO) a member of The UK Government regulatory agency …The Medicines Commission…advisor to the Cabinet Office on the Human Genome project; a member of the Prime Minister’s Task force on the Competitiveness of the Pharmaceutical Industry (PICTF) and Chair of the UK Government Advisory Group on Genetics Research.

Prof Jayne Lawrence
Jayne is Professor and Head of the Pharmaceutical Biophysics Group. She is currently on a 50% secondment at the Royal Pharmaceutical Society (RPS) as their Chief Scientist. At the RPS Jayne is responsible for science and research, performing a variety of roles including working with other scientific organisations and the media and ensuring that the RPS and its membership is up to date with the latest scientific developments in pharmacy. This is a role she has performed since 2007. At King’s, Jayne’s research has focussed on improving the delivery of low molecular weight drugs and biomolecules such as DNA and siRNA using a range of novel and conventional surfactant/polymer and lipid molecules. Jayne is particularly interested in understanding how the structure of a molecule influences the molecular architecture of the delivery vehicle it forms and its fate in the target cell. To achieve these aims Jayne uses a range of advanced analytical techniques including light and neutron scattering and reflectivity. Jayne sits on a number of national committees including the Academy of Pharmaceutical Sciences (Vice-Chair), the United Kingdom and Ireland Controlled Release Society (Treasurer) and the Joint Pharmaceutical Analysis Group, the Institute of Physics and Royal Society of Chemistry’s Joint Neutron Group. She has recently been appointed Vice-Chair of the Formulation and Pharmaceutical Technology Special Interest Group for the International Pharmaceutical Federation. Jayne is a pharmacist, having completed a BSc in Pharmacy at Liverpool Polytechnic and undertaken a year’s pre-registration training in community and industrial pharmacy. After qualifying as a pharmacist Jayne undertook a PhD at Manchester University under the supervision of Professors Peter Elworthy and David Attwood. Jayne started her academic career as a lecturer in Pharmacy at Chelsea College, which subsequently merged with King’s College. Jayne has spent sabbaticals working in the pharmaceutical industry and retains excellent links with the industry.

Dr Michael Leane
Michael Leane is a Principal Scientist with Bristol-Myers Squibb. He graduated with a Pharmacy degree from Trinity College Dublin and has a PhD in Advanced Drug Delivery from the University of Nottingham. He has previously worked at Elan Pharmaceutical Technologies focusing primarily on the development of new solid dosage form delivery systems for poorly permeable drugs and at Phaeton Research investigating novel gastroretentive platforms. He joined Bristol-Myers Squibb in 2005, with an initial role as formulation scientist leading a team concentrating on development of a poorly-soluble compound. His current role at BMS is within drug product development where he specialises in the optimisation of API particle properties to facilitate drug product manufacture. He is a committee member and former chair of the APS Materials Science Focus Group and has authored and co-authored a number of publications around amorphous formulation development and novel characterisation techniques. He is co-lead of an APS-sponsored working group aiming to establish a Manufacturing Classification System for oral solid dosage forms. This initiative developed from an APS conference in 2013 and has grown through the publication of a peer-reviewed position paper and interaction with other international pharmaceutical science bodies such as the AAPS and APV.

Dr Mark McAllister
Dr Mark McAllister is a team leader in the Research Formulation group of Pfizer, PGRD, in Sandwich, UK. He graduated in Pharmacy from Queens University Belfast in 1990 and completed an industrial/hospital pre-registation year before commencing a PhD programme (development of liposomal polymyxin for the treatment of cystic fibrosis) at Aston University with Prof. Oya Alpar. His first industrial appointment at Hoechst-Roussel, Swindon, provided experience working with silicone-based hormone sustained-release. Mark moved to SmithKline Beecham in 1995 where he gained experience in drug absorption profiling, biopharmaceutics and early phase candidate assessment. As a manager within the Strategic Technologies department of GlaxoSmithKline Pharmaceutical Development in Harlow, he was responsible for a number of technology development programmes spanning areas such as oral modified-release and bioenhancement. Since joining Pfizer in 2008, he has continued his research interests in biopharmaceutics and provides formulation support for programmes from early discovery through to proof-of-concept stage.

Prof Yvonne Perrie
Professor Yvonne Perrie is Professor in Drug Delivery within the Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Scotland. She has a BSc (First-Class Hons) in Pharmacy from Strathclyde University, and a PhD from the University of London under the supervision of Prof Gregoriadis. Yvonne’s research is multi-disciplinary and focused on the development of drug carrier systems for the delivery of drugs and vaccines. Yvonne is Editor-in-Chief of the Journal of Liposome Research and Pharmaceutics and Associate Editor for the Journal of Drug Targeting and the Journal of Pharmacy and Pharmacology.

Dr John Wahlich
John is a consultant in the pharmaceutical sciences with over 30 years’ experience in product development. John is a chemist by training (PhD from Nottingham School of Pharmacy) and has analytical and formulation expertise gained from leadership roles in product line extensions, physical properties and early stage development in GlaxoSmithKline

Prof Steve Wicks
Steve is a pharmaceutical scientist with 40 years of experience in drug development and industrial pharmacy. He is currently Emeritus Professor of Pharmaceutical Sciences within the University of Greenwich Faculty of Science and Engineering. He is a volunteer consultant for the University of Greenwich Medway Centre for Pharmaceutical Science coaching early career researchers to solve industrial problems whilst gaining the skills and experience to become the next generation of scientific leaders in the pharmaceutical industry. He is a visiting Professor of Industrial Pharmacy, the University of Bath, UK, an Honorary Fellow, the University College London School of Pharmacy, UK and a former member of the Industrial Advisory Panel, the Department of Materials Science and Metallurgy, the University of Cambridge, UK. His industrial career comprised positions at: Glaxo Pharmaceuticals Ltd (now part of GSK) in 1982 as a laboratory formulation scientist and Abbott Laboratories, UK as a formulation Program Manager. He joined Pfizer in 1986 and in a 24-year career climbed the scientific ladder to become the Global Head of Pharmaceutical Development Science and Technology. This carried with it responsibility for over 1,000 scientists and technologists conducting research in pharmaceutical, process chemical, inhalation device and analytical chemistry engaged in late-stage development and commercialisation activities. He was elected to the Pfizer UK Group Ltd board as one of two research directors to participate in the wider management of Pfizer’s UK business. He is a Fellow of the UK Academy of Pharmaceutical Sciences Advisory Board and serves on the Pharmacy Expert Panels for the British and European Pharmacopoeias. Steve has been a Member of the Royal Pharmaceutical Society of Great Britain since 1981 and was elected Fellow in 2006. He is a retired pharmacist and has been a listed European Qualified Person since 1985. He works as a scientific to pharmaceutical companies in the UK, EU, Norway, India, the US and Australia.

APS Scientific Administrator:

Dr Carol O'Connor
Carol has over 20 years drug development, managerial and project management experience working in the biotechnology, pharmaceutical and device industries. She is a registered Pharmacist with a PhD from the University of Manchester, in controlled drug release Her background is in pharmaceutical development and CMC regulatory affairs with scientific and technical knowledge in drug delivery combined with business and commercial skills. This she has gained from a career working for initially Fisons and then Astra Zeneca in Pharmaceutical development and project management. Moving into Programme Management with Quadrant Healthcare working with novel particle technologies and biologicals, with a range of partnering companies. She is currently a consultant, involved in a range of projects at all stages of drug development, for in house development and partnering from small start-up companies to multinational companies.

APS Secretariat:

Mr Chris Barron
Chris is Client Relationship Manager at AssociAction Enterprises - the APS Secretariat. Chris has extensive knowledge of a wide range of events gained over many years in the entertainment and events business. Chris is also an experienced manager in IT and Resources.